Clinical-stage biopharmaceutical developing stem cell therapies for rare pediatric skeletal diseases.
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Funding round Danish company BOOST Pharma raised €3M from Sound Bioventures, with Industrifonden and Karolinska Development, to advance the BT-101 stem cell therapy for osteogenesis imperfecta. | $3.5M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.